Profusa (NASDAQ:PFSA – Get Free Report) is one of 28 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its peers? We will compare Profusa to related businesses based on the strength of its dividends, risk, profitability, analyst recommendations, earnings, institutional ownership and valuation.
Institutional and Insider Ownership
9.8% of Profusa shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 11.4% of Profusa shares are owned by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Profusa and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Profusa | N/A | -$8.71 million | -1.35 |
| Profusa Competitors | $59.55 million | -$32.15 million | 4.02 |
Analyst Ratings
This is a breakdown of current ratings and price targets for Profusa and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profusa | 1 | 0 | 0 | 0 | 1.00 |
| Profusa Competitors | 76 | 75 | 156 | 6 | 2.29 |
As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 49.76%. Given Profusa’s peers stronger consensus rating and higher possible upside, analysts clearly believe Profusa has less favorable growth aspects than its peers.
Profitability
This table compares Profusa and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profusa | N/A | N/A | -880.32% |
| Profusa Competitors | -672.41% | -133.75% | -59.01% |
Risk & Volatility
Profusa has a beta of -0.14, suggesting that its stock price is 114% less volatile than the S&P 500. Comparatively, Profusa’s peers have a beta of 1.76, suggesting that their average stock price is 76% more volatile than the S&P 500.
Summary
Profusa peers beat Profusa on 10 of the 13 factors compared.
About Profusa
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
